Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Autogene cevumeran - Genentech

Next Previous
X
Search
Drug Profile

Autogene cevumeran - Genentech

Alternative Names: BNT-122; BNT122/RO7198457; Individualized Neoantigen Specific immunotherapy; iNeST; IVAC_M_uID; PCV RO7198457; Personalized cancer vaccine RO7198457; RG-6180; RG6180-1; RO-7198457

Latest Information Update: 19 Feb 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioNTech
  • Developer BioNTech; Genentech; Memorial Sloan-Kettering Cancer Center; Roche
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Adenocarcinoma; Colorectal cancer; Malignant melanoma; Urogenital cancer
  • Phase I Pancreatic cancer; Solid tumours; Triple negative breast cancer

Most Recent Events

  • 21 Jan 2025 Genentech completes phase-II IMCODE001 clinical trials in Malignant melanoma (Combination therapy, First-line therapy, Late-stage disease, In the elderly, In adults) in Australia, US, Belgium, Germany, Spain and United Kingdom (IV) (NCT03815058) (EudraCT2018-001773-24)
  • 05 Aug 2024 Immunogenicity data from a phase II trial in Colorectal cancer released by BioNTech
  • 31 Jul 2024 Phase-II clinical trials in Urogenital cancer (Combination therapy, Adjuvant therapy) in Australia (IV) (NCT06534983)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top